GSK teams up with Strathclyde and University of Nottingham

pharmafile | July 16, 2019 | News story | Manufacturing and Production GSK, GlaxoSmithKline, UK, britain, pharma, universities 

GlaxoSmithKline has teamed up with the University of Nottingham and the University of Strathclyde for a five-year partnership aimed at promoting new medical research.

The £12.9 million project has received £5.5 million in funding from the Engineering and Physical Sciences Research Council (ESPRC).

The partnership will see the three organisations team up to use machine learning and AI to identify new medicines and make the production of medicines more environmentally friendly.  

The project is also intended to train a new cohort of postgraduate students and postdoctoral researchers.

Tony Wood, Senior Vice President, Medicinal Science & Technology at GSK said: “We are delighted with the EPSRC award which recognises the important work being done in collaboration with Nottingham and Strathclyde Universities. 

“Together we are focused on the application of Artificial Intelligence/Machine Learning in synthetic chemistry, a discipline that is central to drug design and development of new medicines. The additional support will enable continued research hopefully delivering efficiency gains that bring meaningful benefit to the discovery of new medicines.” 

Louis Goss

Related Content

GSK shares results from phase 3 trial for gonorrhoea treatment

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …

GSK’s meningococcal vaccine candidate accepted for FDA review

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …

GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment

GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase …

Latest content